Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Donna Weber

Showing results (21-30 of 39) with videos related to

Pageof 4
Sort By:
Blood|May 6, 2003
166Ho-DOTMP plus melphalan followed by peripheral blood stem cell transplantation in patients with multiple myeloma: results of two phase 1/2 trialsSergio Giralt, William Bensinger, Mark Goodman, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|August 16, 2011
Adjusting for patient crossover in clinical trials using external data: a case study of lenalidomide for advanced multiple myelomaK Jack Ishak, J Jaime Caro, Mark T Drayson, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 24, 2007
Results of a retrospective single institution analysis of targeted skeletal radiotherapy with (166)Holmium-DOTMP as conditioning regimen for autologous stem cell transplant for patients with multiple myeloma. Impact on transplant outcomesAnna V Christoforidou, Rima M Saliba, Patricia Williams, et al.
Leukemia & Lymphoma|July 24, 2018
High-risk myeloma and minimal residual disease postautologous-HSCT predict worse outcomesBei Hu, Peter Thall, Denái R Milton, et al.
Journal of Hematology & Oncology|June 25, 2015
Waldenström macroglobulinemia with extramedullary involvement at initial diagnosis portends a poorer prognosisXin Cao, Qing Ye, Robert Z Orlowski, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 20, 2009
Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myelomaUday Popat, Rima Saliba, Rupinderjit Thandi, et al.
Journal of Hematology & Oncology|June 3, 2014
Electroacupuncture for thalidomide/bortezomib-induced peripheral neuropathy in multiple myeloma: a feasibility studyM Kay Garcia, Lorenzo Cohen, Ying Guo, et al.
Haematologica|August 19, 2021
Melphalan dose intensity for autologous stem cell transplantation in multiple myelomaSamer A Srour, Denái R Milton, Qaiser Bashir, et al.
Haematologica|January 11, 2020
New paradigm for radiation in multiple myeloma: lower yet effective dose to avoid radiation toxicityAdnan Elhammali, Behrang Amini, Ethan B Ludmir, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 6, 2007
Multiple myeloma. Clinical practice guidelines in oncologyKenneth C Anderson, Melissa Alsina, William Bensinger, et al.
Pageof 4

Showing results (21-30 of 39) with videos related to

Sort By:
Pageof 4
Blood|May 6, 2003
166Ho-DOTMP plus melphalan followed by peripheral blood stem cell transplantation in patients with multiple myeloma: results of two phase 1/2 trialsSergio Giralt, William Bensinger, Mark Goodman, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|August 16, 2011
Adjusting for patient crossover in clinical trials using external data: a case study of lenalidomide for advanced multiple myelomaK Jack Ishak, J Jaime Caro, Mark T Drayson, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 24, 2007
Results of a retrospective single institution analysis of targeted skeletal radiotherapy with (166)Holmium-DOTMP as conditioning regimen for autologous stem cell transplant for patients with multiple myeloma. Impact on transplant outcomesAnna V Christoforidou, Rima M Saliba, Patricia Williams, et al.
Leukemia & Lymphoma|July 24, 2018
High-risk myeloma and minimal residual disease postautologous-HSCT predict worse outcomesBei Hu, Peter Thall, Denái R Milton, et al.
Journal of Hematology & Oncology|June 25, 2015
Waldenström macroglobulinemia with extramedullary involvement at initial diagnosis portends a poorer prognosisXin Cao, Qing Ye, Robert Z Orlowski, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 20, 2009
Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myelomaUday Popat, Rima Saliba, Rupinderjit Thandi, et al.
Journal of Hematology & Oncology|June 3, 2014
Electroacupuncture for thalidomide/bortezomib-induced peripheral neuropathy in multiple myeloma: a feasibility studyM Kay Garcia, Lorenzo Cohen, Ying Guo, et al.
Haematologica|August 19, 2021
Melphalan dose intensity for autologous stem cell transplantation in multiple myelomaSamer A Srour, Denái R Milton, Qaiser Bashir, et al.
Haematologica|January 11, 2020
New paradigm for radiation in multiple myeloma: lower yet effective dose to avoid radiation toxicityAdnan Elhammali, Behrang Amini, Ethan B Ludmir, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 6, 2007
Multiple myeloma. Clinical practice guidelines in oncologyKenneth C Anderson, Melissa Alsina, William Bensinger, et al.
Pageof 4